Pacira Pharmaceuticals, Inc. (PCRX)

Company Description

Pacira Pharmaceuticals is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the US in April 2012. EXPAREL and two other products have utilized the PCRX proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.


5 Sylvan Way
Parsippany, NJ 07054
United States

973-254 3560


Get BioInvest's perspective on Pacira's CEO

Latest Company News

Market Focus – Tracking These Shares: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Rives Journal - 5 hours ago Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)'s 12 month volatility is currently 60.536500. The 6 month volatility is 57.471200, and the 3 month is noted at 60.777400. [...]
Fri, Mar 24, 2017 8:03:00 PM, Continue reading at the source
Numeric Investors LLC Invests $239000 in Pacira Pharmaceuticals Inc (PCRX) The Cerbat Gem - 9 hours ago Pacira Pharmaceuticals logo Numeric Investors LLC acquired a new position in shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. Pacira Pharmaceuticals Inc (PCRX) Price Target Cut to $54.00 by Analysts at Mizuho - Chaffey Breeze The Mizuho Cuts Pacira Pharmaceuticals Inc (PCRX) Price Target to $54.00 - Petro Global News 24 [...]
Fri, Mar 24, 2017 4:30:00 PM, Continue reading at the source
What are Analysts Expecting for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX ... Aiken Advocate - 12 hours ago Analysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. [...]
Fri, Mar 24, 2017 1:41:00 PM, Continue reading at the source
What's Happening To These Stocks? – Diplomat Pharmacy, Inc. (DPLO), Pacira ... Post Analyst - 18 hours ago Turning to Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), its shares were trading at $46.95 a retreat of $-1.2, on the trading floor. [...]
Fri, Mar 24, 2017 7:50:00 AM, Continue reading at the source
Pacira Pharmaceuticals Inc (PCRX) is trading at a 41% discount to its ... Simply Wall St - Mar 23, 2017 How far off is Pacira Pharmaceuticals (NASDAQ:PCRX) to its intrinsic value? I am going to take a look now by taking the expected future cash flows and discounted them to the value today. [...]
Thu, Mar 23, 2017 4:41:00 PM, Continue reading at the source
Pacira Pharmaceuticals, Inc. (PCRX) : How Do the Technicals Stack Up? The USA Commerce - Mar 23, 2017 We have gathered the technical data on Pacira Pharmaceuticals, Inc. (PCRX), and see some interesting trends in the stock's behavior of late. [...]
Thu, Mar 23, 2017 1:41:00 PM, Continue reading at the source
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease ... GlobeNewswire (press release) - Mar 16, 2017 PARSIPPANY, N. J. and LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Trinity Health, one of the largest hospital systems in the nation, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced they will collaborate to develop an ... [...]
Thu, Mar 16, 2017 11:26:00 AM, Continue reading at the source
Why Pacira Pharmaceuticals Stock Is Already Up 56% This Year Motley Fool - Mar 15, 2017 This is Pacira Pharmaceuticals. Is that how you pronounce this one? Todd Campbell: I pronounce it differently, but we can go with that. Pacira Pharmaceuticals stock rises 2% on positive late-stage trial for opioid ... - MarketWatch Piper Jaffray Companies Reiterates Overweight Rating for Pacira ... - Chaffey Breeze [...]
Wed, Mar 15, 2017 1:41:00 PM, Continue reading at the source
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate ... GlobeNewswire (press release) - Mar 6, 2017 PARSIPPANY, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes ... Pacira Pharmaceuticals Inc. (PCRX) Is Down Following Offering Announcement - RTT News Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal ... - Yahoo Finance [...]
Mon, Mar 06, 2017 9:01:00 PM, Continue reading at the source
Why Earnings Season Could Be Great for Pacira Pharmaceuticals (PCRX) Yahoo Finance - Feb 28, 2017 Investors are always looking for stocks that are poised to beat at earnings season and Pacira Pharmaceuticals, Inc. PCRX may be one such company. Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update - GlobeNewswire (press release) Pacira Pharmaceuticals Inc. (PCRX) Moves Lower on Volume Spike for February 28 - [...]
Tue, Feb 28, 2017 2:37:00 PM, Continue reading at the source